Official Title
Observational Study on the Use of Canakinumab Administered Subcutaneously in the Treatment of Patients With COVID-19 Pneumonia
Brief Summary
The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.
Unknown status
COVID-19
Drug: Canakinumab 150 MG/ML [Ilaris]
COVID-19
Eligibility Criteria
Inclusion Criteria:
- patients with COVID 19 who have received or are candidates to receive treatment with
canakinumab subcutaneously
- Age> 18 years
- Pneumonia diagnosed with Chest X-ray / or Chest CT
Exclusion Criteria:
- Patients with Covid19-related pathology in the context of another cause of major
admission (trauma, surgery)
Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 100 Years
AUSL Romagna Rimini
NCT Number
MeSH Terms
COVID-19
Pneumonia
Antibodies, Monoclonal